News
Scoping review of preclinical and clinical studies on the role of HMGB1 in heart disease - npj Cardiovascular Health
8+ hour, 46+ min ago (1737+ words) A potential novel therapeutic avenue for improving outcomes in cardiac disease involves targeting alarmins, endogenous danger signals capable of modulating both pathological inflammation and physiological repair9. Among these, High Mobility Group Box 1 (HMGB1) is the most extensively characterised9. HMGB1 can be actively secreted by…...
Guest column: More than just a flu shot " the unexpected power of vaccines
1+ hour, 16+ min ago (408+ words) By: Dr. Mehdi Aloosh What if your flu shot did more than protect you from the flu? What if it also lowered your risk of a heart attack or stroke? What if the shingles vaccine helped protect you from dementia,…...
Conavi Medical to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
1+ hour, 46+ min ago (131+ words) April 09, 2026 7: 00 AM EDT | Source: Bloom Burton & Co. Inc. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of…...
NEUPATH HEALTH TO PRESENT AT THE 2026 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE
1+ hour, 16+ min ago (393+ words) TORONTO, April 09, 2026--Neu Path Health Inc. (TSXV: NPTH), ("Neu Path" or the "Company") operates one of Canada's largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other…...
OPKO Health's Mode X Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
1+ day, 34+ min ago (603+ words) The Manila Times OPKO Health's Mode X Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 Subjects dosed in Phase 1 study evaluating safety and tolerability of a first-in-class multispecific antibody WESTON, Mass. , April 08, 2026 (GLOBE NEWSWIRE) -- Mode X Therapeutics Inc....
Invivyd upsizes COVID-19 trial, targets measles antibody By Investing. com
1+ hour, 33+ min ago (232+ words) Iran prepares for U. S. talks as Hormuz curbs and Lebanon fighting cloud truce Oil rebounds as Lebanon strikes test ceasefire, Hormuz disruptions persist Goldman trims Q2 oil price forecast after ceasefire deal, keeps medium-term view U. S. -Iran ceasefire deal fails to erase worries…...
Pfizer Inc To Discuss Data From An Ongoing Phase 1/2 Study Of m RNA-Based Vaccine Candidate Against SARS-Co V-2 Call Transcript
13+ hour, 17+ min ago (62+ words) Guru Focus Pfizer Inc To Discuss Data From An Ongoing Phase 1/2 Study Of m RNA-Based Vaccine Candidate Against SARS-Co V-2 Call Transcript We'd love to learn more about your experiences on Guru Focus. com and how we can improve!...
US CDC delays publishing report showing COVID vaccine benefits, Wa Po reports
3+ hour, 30+ min ago (132+ words) April 9 (Reuters) - The acting director of the "Centers for "Disease Control and Prevention has delayed publication of a "CDC "report "showing the COVID-19 "vaccine cut the likelihood of emergency department visits "and hospitalizations for healthy "ad. .. April 9 (Reuters) " The acting…...
Could our nose cells be key to preventing future pandemic spread?
2+ hour, 2+ min ago (534+ words) Deadly respiratory viruses, like those causing COVID-19 and flu, spread among people through a simple act: breathing. With each inhalation, these airborne pathogens enter the body through our noses, throat and lungs, and replicate in the infected person before being…...
Could cells in our nose be key to preventing future pandemic spread?
2+ hour, 32+ min ago (536+ words) Securing the Future: CEPI 3. 0 Investment Case Deadly respiratory viruses, like those causing COVID-19 and flu, spread among people through a simple act: breathing. With each inhalation, these airborne pathogens enter the body through our noses, throat and lungs, and replicate…...